Table 3 Risk of death during follow-up according to clinicopathological factors in the entire cohort
Factor | Unadjusted | Adjusted | ||
|---|---|---|---|---|
n (events) | HR (95% CI) | n (events) | HR (95% CI) | |
Age | ||||
Continuous | 355 (166) | 1.06 (1.04-1.09) | 342 | 1.05 (1.03-1.08) |
Gender | ||||
Female | 109 (42) | 1.00 | 103 (38) | 1.00 |
Male | 246 (124) | 1.30 (0.92-1.85) | 239 (122) | 1.17 (0.81-1.70) |
Stage | ||||
Ta | 163 (63) | 1.00 | 163 (63) | 1.00 |
T1 | 97 (42) | 1.61 (1.09-2.39) | 97 (42) | 1.16 (0.73-1.82) |
T2 | 64 (48) | 3.97 (2.71-5.82) | 64 (48) | 2.60 (1.60-4.23) |
T3-4 | 6 (5) | 13.13 (5.16-33.39) | 6 (5) | 7.81 (2.99-20.41) |
Tis | 12 (2) | 0.38 (0.09-1.56) | 12 (2) | 0.42 (0.10-1.71) |
Grade | ||||
Low | 183 (65) | 1.00 | 182 (64) | 1.00 |
High | 150 (96) | 2.54 (1.85-3.48) | 148 (94) | 1.73 (1.14-2.62) |
Location | ||||
Bladder | 335 (158) | 1.00 | 327 (153) | 1.00 |
Other | 15 (7) | 0.84 (0.39-1.79) | 15 (7) | 0.87 (0.38-1.95) |
Smoking | ||||
Regularly | 125 (64) | 1.00 | 120 (61) | 1.00 |
Occasionally | 23 (9) | 0.63 (0.31-1.26) | 23 (9) | 0.69 (0.34-1.42) |
Former | 155 (71) | 0.84 (0.60-1.18) | 150 (71) | 0.87 (0.61-1.25) |
Never | 52 (22) | 0.81 (0.50-1.31) | 49 (19) | 0.86 (0.50-1.48) |